このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行がん患者に対する DS-8201a の生物学的効果の試験

2026年10月29日 更新者:National Cancer Institute (NCI)

HER2発現進行性固形腫瘍患者におけるDS-8201a薬力学のパイロット研究

This phase I trial studies the biological effects of trastuzumab deruxtecan (DS-8201a) on patients with human epidermal growth factor receptor 2 (HER2) positive cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the tumor cells by damaging their deoxyribonucleic acid (DNA), resulting in tumor cell death. This study looks at how DS-8201a may affect the levels of certain proteins and immune cells in tumors and how well the drug works against tumor cells by examining cells from a small piece tumor taken before and after DS-8201a is given.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To assess the effects of trastuzumab deruxtecan (DS-8201a) on total Top1 levels in biopsy specimens from patients with human epidermal growth factor receptor 2 (HER2) -expressing advanced solid tumors, at early and late post-treatment time points, thereby establishing the degree and duration of DS-8201 target engagement.

SECONDARY OBJECTIVES:

I. To assess any associations between serum concentrations of DS-8201a and the effects of DS-8201a on total Top1 levels in tumor biopsy specimens.

II. To determine the safety and tolerability of DS-8201a administered intravenously every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.

III. To determine the overall response rate (complete response [CR] + partial response [PR]) for patients administered intravenously with DS-8201a every 3 weeks, in 21-day cycles, at a dose of 5.4 mg/kg.

EXPLORATORY OBJECTIVES:

I. To evaluate the effects of DS-8201a on cluster of differentiation 8 (CD8+) T cell infiltration and activation in tumor, tumor programmed death-ligand 1 (PD-L1) and HER2 expression, and deoxyribonucleic acid (DNA) damage response (DDR) signaling (for example: gamma H2A histone family member X (H2AX), radiation sensitive 51 (RAD51), and phosphorylated [p]Nibrin (NBS1) in biopsy specimens.

II. To examine genomic alterations in circulating tumor DNA (ctDNA) that may be associated with DS-8201a response or resistance.

III. To examine any associations between baseline tumor HER2 amplification or HER2 expression level and response to DS-8201a.

IV. To evaluate the effects of DS-8201a on tumor levels of HER2 and DDR-associated proteins.

V. To examine any tumor genomic alterations that may be associated with resistance to DS-8201a.

VI. To evaluate anti-drug antibodies following administration of DS-8201a.

OUTLINE:

Patients receive trastuzumab deruxtecan intravenously (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.

After completion of study treatment, patients are followed up for 40 days.

研究の種類

介入

入学 (実際)

62

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center
      • Bethesda、Maryland、アメリカ、20892
        • National Cancer Institute Developmental Therapeutics Clinic
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Dana-Farber Cancer Institute
    • New York
      • New York、New York、アメリカ、10065
        • NYP/Weill Cornell Medical Center
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • University of Pittsburgh Cancer Institute (UPCI)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

  • Patients must have measurable or evaluable disease

  • Age >= 18 years of age

  • Patients must have human epidermal growth factor receptor 2 (HER2)-positive or HER2-expressing tumors as defined by Clinical Laboratory Improvement Act (CLIA)-certified labs. Patients must have either:

    • A tumor HER2 immunohistochemistry (IHC) score of 1+ or greater (as determined by a CLIA-certified IHC test, per criteria specified) or
    • A tumor with HER2 amplification (as determined by CLIA-certified in situ hybridization [ISH] or a CLIA-certified next-generation sequencing assay)
  • Patients with HER2 mutations are eligible, as are patients with HER2-positive breast cancer

  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Absolute neutrophil count >= 1,500/mcL (within 8 days of enrollment)

  • Platelets >= 100,000/mcL (within 8 days of enrollment)

  • Leukocytes >= 3,000/mcL (within 8 days of enrollment)

  • Hemoglobin >= 9 g/dL (>= 8.0 g/dL for gastric cancer [GC] only) (within 8 days of enrollment)

  • Serum albumin >= 2.5 g/dL group-specific component (GC only) (within 8 days of enrollment)

  • Total bilirubin =< 1.5 x institutional upper limit of normal (=< 3 x upper limit of normal in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 8 days of enrollment)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal OR =< 5 x institutional upper limit of normal for patients with liver metastases at baseline (within 8 days of enrollment)

  • Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional normal (within 8 days of enrollment)

  • No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment

  • No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment

  • International normalized ratio (INR)/prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) =< 1.5 x upper limit of normal (ULN)

  • Ability to understand and the willingness to sign a written informed consent document

  • Willingness to provide blood samples for research purposes

  • Patients must have a lesion or lesions amenable to biopsy and must be willing to undergo 3 core needle biopsy procedures for research purposes

  • Patients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO), multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI) scan within 28 days prior to enrollment

  • Patients receiving standard of care androgen deprivation treatment (surgical castration versus luteinizing hormone-releasing hormone [LHRH] agonist or antagonist treatment) are eligible to participate in the trial. Patients receiving LHRH agonist or antagonist may continue treatment throughout the duration of this study

  • Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:

    • They must be stable on their anti-retroviral regimen, and they must be healthy from an human immunodeficiency virus (HIV) perspective

    • They must have a cluster of differentiation 4 (CD4) count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/uL over the past 2 years, unless it was deemed related to the cancer and/or immunotherapy-induced bone marrow suppression

      • For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/ul during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy
    • They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 8 days of enrollment

    • They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for >= 1 month after treatment of the brain metastases

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • The effects of trastuzumab deruxtecan (DS-8201a) on the developing human fetus are unknown. For this reason and because HER2 antibodies conjugated to topoisomerase 1 inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation and for at least 7 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a administration

  • Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method

  • Subjects must not freeze, donate, or retrieve for their own use ova or sperm starting at screening, throughout the study period, and for at least 4.5 months after the final study drug administration. Preservation of sperm or ova should be considered prior to enrollment in this study

  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a

Exclusion Criteria:

  • Patients who have had:

    • Chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer-with the exception of standard of care androgen deprivation treatment) within:

      • 4 weeks or five half-lives, whichever is shorter, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel or
      • 6 weeks for nitrosoureas or mitomycin C or
    • Immunotherapy, including monoclonal antibody therapy, within 4 weeks

  • Patients with any of the following pulmonary-related illnesses:

    • A history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or for whom suspected ILD/pneumonitis cannot be ruled out by imaging at screening
    • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD] grade 3-4 per Global Initiative for Obstructive Lung Disease [GOLD] criteria, restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (i.e., Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy
  • Patients who have had radiation therapy within 4 weeks (or palliative stereotactic radiation therapy within 2 weeks)

  • Patients who have had a major surgery within 4 weeks

  • Patients who are receiving any other investigational agents

  • Patients with a medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association class II to IV), or with troponin levels consistent with myocardial infarction (as defined according to the assay manufacturer) 28 days prior to enrollment

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a (e.g., other topoisomerase I inhibitors) or the inactive ingredients in the drug product

  • Patients who have a history of severe hypersensitivity reactions to other monoclonal antibodies

  • Patients with a Fridericia's formula-corrected QT interval (QTcF) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram (ECG)

  • Patients with spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms

  • Patients with an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals

  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade =< 1 or baseline. Subjects with chronic grade 2 toxicities (e.g., grade 2 chemotherapy-induced neuropathy) may be eligible per the discretion of the investigator after consultation with the sponsor medical monitor or designee. Subjects should no longer be symptomatic nor require treatment with corticosteroids or anticonvulsants and must have recovered from the acute toxic effect of radiotherapy

  • Patients with substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the investigator

  • Patients with uncontrolled intercurrent illness

  • Patients with psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant women are excluded from this study because DS-8201a is a HER2 antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a

  • Patients are not allowed to receive chloroquine/hydroxychloroquine. Patients receiving chloroquine/hydroxychloroquine require a washout of > 14 days

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (trastuzumab deruxtecan)

Patients receive trastuzumab deruxtecan intravenous (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.

Undergo biopsy

他の名前:
  • Bx
  • BIOPSY_TYPE
  • 生検

Undergo collection of blood samples

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集

Undergo magnetic resonance imaging (MRI)

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo echocardiogram (ECHO)

他の名前:
  • 心エコー図
  • 心エコー検査
  • EC

Undergo computerized tomography (CT) scan

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo multi-gated acquisition scan (MUGA)

他の名前:
  • 血液プールスキャン
  • 平衡放射性核種血管造影
  • ゲーテッド血液プールイメージング
  • ムガ
  • 放射性核種心室造影
  • RNVG
  • SYMAスキャン
  • 同期マルチゲート取得スキャン
  • ムガスキャン
  • マルチゲート取得スキャン
  • 放射性核種脳室造影スキャン
  • ゲーテッドハートプールスキャン
  • RNVスキャン

Given intravenous (IV)

他の名前:
  • エンヘルトゥ
  • DS-8201a
  • T-DXd
  • DS-8201
  • ファムトラスツズマブ
  • WHO 10516

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points
時間枠:(Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days

Change (i.e., decrease) in total TOP1 protein as measured by the percentage of nuclear area staining positive (%NAP) for TOP1 in biopsies collected after trastuzumab deruxtecan (DS-8201a) treatment compared to baseline biopsies using a quantitative immunofluorescence assay. We do not have any evidence regarding whether an increase or decrease in total TOP1 %NAP after treatment increases the likelihood of the tumor responding to the drug.

(Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment
時間枠:Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days

The change in the number of active immune cells in each participants' tumor after treatment with trastuzumab deruxtecan (DS-8201a) compared with baseline, as measured by the number of cells per square millimeter within the tumor that stain positive for both the Cluster of Differentiation 8 (CD8+) protein and the T-cell receptor T3 zeta chain (CD3ζ) protein phosphorylated at Tyrosine 142 (CD3ζ pY142+) using a quantitative immunofluorescence assay. Larger or increasing numbers of active immune cells in the tumor are thought to increase the likelihood of the tumor responding to the drug.

Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies
時間枠:Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days

The association between serum concentrations of trastuzumab deruxtecan (DS-8201a) and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a serum concentration at the timepoint closest to the biopsy and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 [C1D2-4] biopsy.

Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)
時間枠:Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose

The association between the maximum serum concentration of trastuzumab deruxtecan (DS-8201a) and the initial change in tumor cells' TOP1 covalent complex (TOP1cc) levels will be assessed by computing the sample correlation between the highest DS-8201a serum concentration observed for each participant during cycle 1 of treatment and the initial change in tumor cells with TOP1cc (from baseline to cycle (C) 1 day (D) 2-4 [C1D2-4] biopsy

Baseline compared to cycle 1 (one cycle = 21 days), 2-4 days post-day 1 dose
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies
時間枠:Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days

Area Under the Curve (AUC) is a calculated estimate of the serum concentration of Trastuzumab Deruxtecan (DS-8201a) over time. It is used to characterize the overall exposure over a time interval. The association between participant trastuzumab deruxtecan (DS-8201a) AUC and the change in total TOP1 levels in tumor biopsies was assessed by computing the sample correlation between the DS-8201a AUC and the initial change in tumor TOP1 level (from baseline to cycle (C) 1 day (D) 2-4 [C1D2-4] biopsy.

Baseline compared to 2-4 days post day 1 dose, for an average of 3.2 days
Number of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant
時間枠:From the start of the treatment until disease progression/recurrence, an average of 6.8 months

Grades 2 and higher adverse events were measured using the Common Terminology Criteria for Adverse Events (CTCAEv5.0). Grade 2 moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.

From the start of the treatment until disease progression/recurrence, an average of 6.8 months
Overall Response Rate
時間枠:From the start of the treatment until disease progression/recurrence, an average of 6.8 months.

The overall response rate (complete response + partial response) among eligible participants who have received at least one dose of trastuzumab deruxtecan (DS-8201a). A 95% confidence interval for this response rate will also be computed. For this analysis, response classifications will follow Response Evaluation Criteria in Solid Tumors version 1.1 guidelines. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm (<1cm). Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Overall response rate is the combination of complete and partial responses.

From the start of the treatment until disease progression/recurrence, an average of 6.8 months.

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
時間枠:Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Adverse Events were monitored/assessed from the start of the treatment until disease progression/recurrence, an average of 6.8 months,

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sarah Shin、National Cancer Institute LAO

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年9月1日

一次修了 (実際)

2025年9月2日

研究の完了 (推定)

2027年1月19日

試験登録日

最初に提出

2020年3月3日

QC基準を満たした最初の提出物

2020年3月3日

最初の投稿 (実際)

2020年3月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2020-01206
  • NCI-2020-01206 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • 20-C-0154
  • P194688
  • 10346 (その他の識別子:CTEP)
  • 10346 (その他の識別子:National Cancer Institute LAO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

National Cancer Institute (NCI) is committed to sharing data in accordance with National Institutes of Health (NIH) policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

IPD 共有時間枠

At the time of publication or shortly thereafter.

IPD 共有アクセス基準

Data will be shared through a National Institutes of Health (NIH) funded or approved public repository: clinicaltrials.gov and Biomedical Translational Research Information System (BTRIS). Approved outside collaborators under appropriate individual agreements. Publication and/or public presentations.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。